 Connection
Christopher Lieu to Pancreatic Neoplasms
This is a "connection" page, showing publications Christopher Lieu has written about Pancreatic Neoplasms.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.094 |
|
|
|
-
Akinlalu A, Rasuleva K, Ogberefor E, Gao T, Han H, Singh PK, Lieu CH, Coughlan C, Pitts TM, Sun D. A Fluorescence Resonance Energy Transfer-Based Assay Targeting Tumor-Derived Extracellular Vesicles for Highly Specific Pancreatic Cancer Detection. ACS Nano. 2025 Dec 23; 19(50):42056-42065.
Score: 0.133
-
Khomiak A, Balmaceda NB, Ghaffar SA, Lieu CH, Del Chiaro M, Messersmith WA, Lentz RW. Oligometastatic pancreatic cancer: current state of management and emerging therapies. Oncologist. 2025 Jun 04; 30(6).
Score: 0.128
-
Ueberroth BE, Lieu CH, Lentz RW. Prolonged Response to Dabrafenib/Trametinib in Grade 3 Metastatic Pancreatic Neuroendocrine Tumor (NET G3) with BRAF V600E Mutation. J Gastrointest Cancer. 2024 Sep; 55(3):1448-1452.
Score: 0.119
-
Hawkins HJ, Yacob BW, Brown ME, Goldstein BR, Arcaroli JJ, Bagby SM, Hartman SJ, Macbeth M, Goodspeed A, Danhorn T, Lentz RW, Lieu CH, Leal AD, Messersmith WA, Dempsey PJ, Pitts TM. Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tumor organoid library (PTOL). PLoS One. 2024; 19(4):e0298808.
Score: 0.118
-
Amo-Aparicio J, Dominguez A, Atif SM, Dinarello A, Azam T, Alula KM, Piper M, Lieu CH, Lentz RW, Leal AD, Bagby SM, Messersmith WA, Karam SD, Dinarello CA, Pitts TM, Marchetti C. Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment. Cancer Res Commun. 2023 09 20; 3(9):1899-1911.
Score: 0.114
-
Stuart CM, Kirsch MJ, Zhuang Y, Meguid CL, Sugawara T, Colborn KL, Messersmith W, Lieu C, Gleisner AL, Del Chiaro M, Schulick RD, Meguid RA. Pulmonary metastasectomy is associated with survival after lung-only recurrence in pancreatic cancer. Surgery. 2023 09; 174(3):654-659.
Score: 0.112
-
Sahin IH, Lin Y, Yothers G, Lucas PC, Deming D, George TJ, Kopetz S, Lieu CH, Dasari A. Minimal Residual Disease-Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US. Oncology (Williston Park). 2022 10 07; 36(10):604-608.
Score: 0.106
-
Oba A, Wu YHA, Lieu CH, Meguid C, Colborn KL, Beaty L, Al-Musawi MH, Davis SL, Leal AD, Purcell T, King G, Wooten ES, Fujiwara Y, Goodman KA, Schefter T, Karam SD, Gleisner AL, Ahrendt S, Leong S, Messersmith WA, Schulick RD, Del Chiaro M. Outcome of neoadjuvant treatment for pancreatic cancer in elderly patients: comparative, observational cohort study. Br J Surg. 2021 08 19; 108(8):976-982.
Score: 0.098
-
Amini A, Jones BL, Stumpf P, Leong S, Lieu CH, Weekes C, Davis SL, Messersmith WA, Purcell WT, Ghosh D, Schefter T, Goodman KA. Patterns of Care for Locally Advanced Pancreatic Adenocarcinoma Using the National Cancer Database. Pancreas. 2017 08; 46(7):904-912.
Score: 0.074
-
Kessler ER, Eckhardt SG, Pitts TM, Bradshaw-Pierce EL, O'byrant CL, Messersmith WA, Nallapreddy S, Weekes C, Spratlin J, Lieu CH, Kane MA, Eppers S, Freas E, Leong S. Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers. Invest New Drugs. 2016 Apr; 34(2):176-83.
Score: 0.067
-
Grey N, Silosky M, Lieu CH, Chin BB. Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors. World J Gastroenterol. 2022 May 07; 28(17):1768-1780.
Score: 0.026
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|